Elaina Adderley, MD
Endocrinology, Diabetes & Metabolism · Montgomery, ALNPI 1699220988
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 402 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 16.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,974, more than ten times the $21 reported in 2019. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in AL, where the typical reported total is $6,650.
Across 402 payments — averaging $17.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Novo Nordisk$782
- Dexcom, Inc.$651
- Bayer$418
- Radius Health, Inc.$395
- Medtronic$379
- plus $3K from 24 others
What the payments were for
- Food & beverage$6,93497%
- Education$1813%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 72 | $1,195 |
| Novo Nordisk | 37 | $782 |
| Dexcom, Inc. | 57 | $651 |
| Bayer | 43 | $418 |
| Radius Health, Inc. | 14 | $395 |
| Medtronic(2 entities) | 5 | $379 |
| Sanofi-aventis U.S. LLC | 17 | $319 |
| Boehringer Ingelheim | 19 | $314 |
| AstraZeneca(2 entities) | 15 | $269 |
| BETA Bionics, Inc. | 11 | $266 |
| Amneal Pharmaceuticals LLC | 18 | $242 |
| Corcept Therapeutics | 12 | $206 |
| Novartis | 11 | $183 |
| Xeris Pharmaceuticals, Inc. | 8 | $182 |
| Mannkind Corporation | 6 | $172 |
| AbbVie | 9 | $158 |
| Antares Pharma, Inc. | 6 | $149 |
| Amgen(2 entities) | 8 | $144 |
| Tandem Diabetes Care, Inc. | 4 | $108 |
| Amryt Pharma Holdings Ltd | 5 | $104 |
| Insulet Corporation | 4 | $91 |
| IBSA Pharma Inc. | 4 | $83 |
| Abbott | 6 | $82 |
| Recordati_rare_diseases_inc. | 3 | $60 |
| Pfizer | 3 | $48 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
| Chiesi USA, Inc. | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| GSK | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SIMPLERA SENSOR$130
How this compares
$7,114 in reported general payments places this provider in the 50th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 570 | $665,209 |
| OzempicSemaglutide | 505 | $576,025 |
| JardianceEmpagliflozin | 240 | $280,058 |
| FarxigaDapagliflozin Propanediol | 127 | $141,162 |
| Tresiba Flextouch U-200Insulin Degludec | 104 | $138,878 |
| TrulicityDulaglutide | 84 | $106,497 |
| TradjentaLinagliptin | 78 | $93,352 |
| Gvoke Hypopen 2-PackGlucagon | 138 | $92,095 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 87 | $61,251 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 51 | $57,994 |
| Tresiba Flextouch U-100Insulin Degludec | 85 | $54,840 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 42 | $48,848 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 33 | $46,573 |
| Humulin R U-500Insulin Regular, Human | 14 | $42,562 |
| KerendiaFinerenone | 39 | $39,768 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog, Baqsimi | $1,195 | $823,340742 claims |
| Novo NordiskOzempic, Rybelsus | $782 | $615,701528 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Glyxambi, Trijardy Xr | $314 | $465,841413 claims |
| AstraZenecaFarxiga | $269 | $141,162127 claims |
| BayerKerendia | $418 | $39,76839 claims |
| AbbVieSynthroid | $158 | $11,756132 claims |
| IBSA Pharma Inc.Tirosint | $83 | $6,08524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
Other endocrinology, diabetes & metabolism in Montgomery
- Hima AmmanaMontgomery$9K
- Manisha GargMontgomery$8K
- Warda NiazMontgomery$8K
- Vaishall ThudiMontgomery$8K
- Ahsan FarooqMontgomery$4K
- Mohammad-Ehsan OwrangiMontgomery$3K
- Neil SchaffnerOpelika$642K
- Ralph TeagueBirmingham$487K
- Bantwal BaligaOpelika$483K
- William GarveyBirmingham$421K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.